Assessing drug-induced dyskinesia in the clinic, the laboratory and the natural environment of patients.
The assessment of drug-induced dyskinesia (DID) in Parkinson's disease represents a formidable challenge for clinicians and researchers alike. The present review describes the current assessment tools used in the clinic, where different scales have been developed for monitoring levels of DID in patients. We also review laboratory tools used to assess the quantity and characteristics of DID. Finally, we review assessment methods currently in development for monitoring DID and voluntary mobility in the natural living environment of patients. Here, we discuss the strengths and weaknesses of these tools as it pertains to their efficacy in assessing the quantity of DID, its characteristics, as well as its impact on the quality of life of patients. Finally, we discuss ongoing challenges and research questions that may guide future development of assessment methods aimed at monitoring DID and its impact on daily lives of patients.
Département des Sciences Biologiques, Université du Québec à Montréal, Montréal, QC, Canada.
Benoit
B
Carignan
Jean-François
JF
Daneault
Christian
C
Duval
D000978:Antiparkinson Agents / Q000009:adverse effects; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D017056:Medical Laboratory Personnel; D010300:Parkinson Disease / Q000188:drug therapy; D011788:Quality of Life
D000978:Antiparkinson Agents